Exploiting the Endogenous Type II ‐A CRISPR ‐Cas System for Functional Engineering of Probiotic Lacticaseibacillus rhamnosus GG
Microbial Biotechnology · 2026-01 · 19 (1)
DOI: 10.1111/1751-7915.70303 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Biotechnology, online erschienen am 20.01.2026. Verfasst von Zifan Xie und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Food Science and Human Nutrition, University of Illinois Urbana-Champaign, Urbana, Illinois, USA. Hauptthemen laut MEDLINE: Lacticaseibacillus rhamnosus, CRISPR-Cas Systems, Probiotics, Gene Editing. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University of Illinois at Urbana-Champaign.
Abstract (Originalsprache)
Lacticaseibacillus rhamnosus GG (LGG) is one of the most extensively studied probiotic strains, widely used in food and health applications. However, the absence of efficient, precise genome editing methods has limited its broader potential and functional versatility. Here, we present an endogenous type II‐A CRISPR‐Cas genome editing workflow for LGG designed for functional strain construction. Using a plasmid interference assay together with single‐nucleotide substitutions, we confirm the precise PAM requirement as 5′‐NGAAA‐3′. We pair a synthetic sgRNA cassette with homology‐directed repair donors to enable targeted deletions and insertions across multiple loci, achieving modest but practically relevant editing efficiencies (11.1‐25.0% of recovered transformants) that support routine strain construction. Using this optimised and precise genome engineering method, we generated a β‐glucuronidase (GUS)‐expressing LGG strain for robust strain tracking within complex microbial communities. This work removes barriers to LGG engineering, expands the probiotic CRISPR toolkit, and provides broadly applicable strategies for designing next‐generation probiotics with applications in food biotechnology and microbial therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Food Science and Human Nutrition, University of Illinois Urbana-Champaign, Urbana, Illinois, USA.
- Carl R. Woese Institute for Genomic Biology, University of Illinois Urbana-Champaign, Urbana, Illinois, USA.
Förderung
- University of Illinois at Urbana-Champaign
Zitieren
APA
Xie, Z., Jin, Y. S., & Miller, M. J. (2026). Exploiting the Endogenous Type II ‐A CRISPR ‐Cas System for Functional Engineering of Probiotic Lacticaseibacillus rhamnosus GG. Microbial Biotechnology, 19(1). https://doi.org/10.1111/1751-7915.70303
Vancouver
Xie Z, Jin YS, Miller MJ. Exploiting the Endogenous Type II ‐A CRISPR ‐Cas System for Functional Engineering of Probiotic Lacticaseibacillus rhamnosus GG. Microbial Biotechnology. 2026;19(1). doi:10.1111/1751-7915.70303
BibTeX
@article{Xie2026,
author = {Xie, Zifan and Jin, Yong-Su and Miller, Michael J},
title = {Exploiting the Endogenous Type II ‐A CRISPR ‐Cas System for Functional Engineering of Probiotic Lacticaseibacillus rhamnosus GG},
journal = {Microbial Biotechnology},
year = {2026},
volume = {19},
number = {1},
doi = {10.1111/1751-7915.70303}
}
EUVIMED